Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 to 75
Other
KMU-IRB00003151
VGHKS95-CT3-11, NCT00656968
Last Modified:
6/6/2008
 
First Published:
9/16/2005
2.
Phase III Randomized Study of Induction Therapy Comprising Two Different Doses of High-Dose Melphalan and Amifostine Followed by Single or Double Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Maintenance Therapy Comprising Clarithromycin, Thalidomide, and Dexamethasone in Patients With Stage II or III Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 70
NCI, Pharmaceutical / Industry
FHCRC-2004.00
MEDIMMUNE-FHCRC-2004.00, NCT00217438
3.
Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 75
Other
HELYX Study
NCT00154440
Last Modified:
12/21/2007
 
First Published:
9/9/2005
4.
Phase II Study of Maintenance Therapy Comprising Thalidomide, Dexamethasone, and Clarithromycin in Patients With Multiple Myeloma Who Have Undergone Prior Autologous or Syngeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Not specified
NCI, Pharmaceutical / Industry
FHCRC-1767.00
CELGENE-FHCRC-1767.00, NCT00182663
Last Modified:
5/15/2007
 
First Published:
3/2/2007
5.
Phase II Study of Maintenance Therapy Comprising Lenalidomide, Dexamethasone, and Clarithromycin in Patients Who Have Undergone Autologous or Syngeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
FHCRC-2135.00
NCT00445692
6.
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Other
07-038
NCT00461084
7.
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
Other
0707009285
RV-MM-PI-238, NCT00538733
8.
Prospective Study of First-Line Antibiotic Therapy for Early-Stage Gastric MALT Lymphoma for Treatment Outcome
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Biomarker/Laboratory analysis, Treatment
Active
No age specified
Other
T3206
NCT00327132
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute